Xuesheng Wang

Dr. Xuesheng Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in BJU International
Verified
Journal Article
Closed access
ZZZhonghan Zhou
Zhonghan Zhou
XWXuesheng Wang
Xuesheng Wang
XLXunhua Li
Xunhua Li
LLLimin Liao
Limin Liao

31 March 2023 in International Neurourology Journal
Verified
Journal Article
Open access
PDF file
XWXuesheng Wang
Xuesheng Wang
ZZZhonghan Zhou
Zhonghan Zhou
LLLimin Liao
Limin Liao
Purpose: We investigated the effectiveness of intravesical botulinum toxin-A (BTX-A) injection therapy in patients with lower urinary tract dysfunction (LUTD) and upper urinary tract (UUT) deterioration and evaluated whether BTX-A injection therapy could substitute for augmentation uretero-enterocystoplasty (AUEC).Methods: Data from a prospective, single-center cohort from 2017–2021 were analyzed. Patients were divided into 2 treatment groups: AUEC and BTX-A (i.e., patients who declined AUEC). Bladder and UUT functions were assessed by comparing clinical information, urodynamic data, laboratory results, and imaging records.Results: In total, 121 patients were enrolled (BTX-A group: 41 patients; AUEC group: 80 patients). The BTX-A group showed a reduced maximum detrusor pressure and increases in the maximum bladder volume and bladder compliance (P<0.05). However, in follow-up evaluations, significantly smaller improvements (all P0.05). Both VUR and UUTD improved significantly in the AUEC group, and the Scr and eGFR levels significantly improved after AUEC relative to baseline levels (P<0.05). The reduction in the Scr level was significantly lower in the BTX-A group than in the AUEC group during 0–15 months of follow-up (Scr reduction differences, -1.36; P<0.01).Conclusions: Although BTX-A injection therapy was effective for improving bladder function, BTX-A injections did not alleviate UUT deterioration in this study, particularly in patients with advanced-stage LUTD. Conversely, AUEC for LUTD has a well-established role in improving UUT function. Hence, BTX-A injection therapy should not replace AUEC to ameliorate UUT impairment and protect UUT function.

8 August 2025 in International Journal of Surgery
Verified
Journal Article
Open access
XWXuesheng Wang
Xuesheng Wang
FZFan Zhang
Fan Zhang
ZZZhonghan Zhou
Zhonghan Zhou
QFQiang Fu
Qiang Fu
LLLimin Liao
Limin Liao
Background: Bladder augmentation with gastrointestinal segments is a widely used surgical procedure for neurogenic bladder, but it carries a risk of many side effects. However, there have been no systematic studies on which biomaterials are suitable for bladder augmentation and reconstruction. The aim of this study was to compare the safety and applicability of small intestinal submucosa (SIS), poly(l-lactic) acid (PLLA) nanofibrous scaffold, and PLLA/gelatin composite nanofibrous scaffold as a potential bladder wall substitute material in tissue-engineered bladder augmentation and reconstruction. The results provide a scientific basis for selecting appropriate materials in clinical applications. Materials and Methods: The microstructure, cytocompatibility, cell adhesion, and histocompatibility of scaffolds including SIS, PLLA nanofiber scaffold, and PLLA/Gelatin were observed. Furthermore, bladder augmentation rabbit models were constructed using scaffolds with and without adipose-derived stem cells (ASCs) implantation. Cystography and urodynamic examination were performed to evaluate the morphology and function of the reconstructed bladder. Histologic and immunofluorescence were used to assess the regeneration status of the reconstructed bladder. Results: Compared to SIS and PLLA/Gelatin scaffolds, the PLLA scaffold possessed appropriate mechanical properties, pore size and porosity, which could facilitate suturing, maintain bladder form, and promote the adhesion and proliferation of seeded ASCs. All animals survived in the experiment with no complications, and the structural integrity of the implantation site was demonstrated using cystography and urodynamics. Histological and immunohistochemical analyses indicated that the three kinds of scaffold could regenerate the bladder wall structure at 6 and 12 weeks. Bladder reconstructed with the ASCs-PLLA scaffold showed superior structural and functional properties, with no significant differences in the regenerated urothelium, smooth muscle, or vessels of the ASCs-PLLA and control groups. Conclusion: The ASCs-PLLA scaffold – composed of PLLA with favorable biological properties and ASCs with facilitating regeneration – presents a promising candidate as an ideal scaffold for bladder augmentation and reconstruction.

14 February 2021 in Andrologia
Verified
Journal Article
Open access
PDF file
ZMZhen Ma
Zhen Ma
MLMing Li
Ming Li
XWXuesheng Wang
Xuesheng Wang
QWQiang Wang
Qiang Wang
MYMingzhen Yuan
Mingzhen Yuan
This study aimed to explore the efficacy of injection of micronised acellular dermal matrix (MADM) particles for treating primary premature ejaculation. This study was a prospective single‐arm clinical trial. Thirty patients who met the surgical indications were enrolled. MADM particles, mixed in platelet‐rich plasma, were injected into Buck's fascia to spread over the dorsal penile nerve, suppress the influx of nerve impulses and, thus, reduce penis sensitivity. We evaluated the changes according to intravaginal ejaculation latency time using a stopwatch and a premature ejaculation diagnostic tool. Meanwhile, we also recorded sexual partner satisfaction and adverse events. All patients recovered well after surgery with no complications such as infections or allergies. The mean intravaginal ejaculation latency time before surgery was 0.72 ± 0.28 min, compared with 2.41 ± 0.54 min, 2.64 ± 0.41 min, 2.79 ± 0.25 min and 2.89 ± 0.35 min at, respectively, 4, 8, 16 and 20 weeks after surgery. The premature ejaculation diagnostic values and sexual partner satisfaction had significantly improved after treatment. Injection of MADM particles is an effective, safe and simple method for treating premature ejaculation.

6 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
WCWeibo Chen
Weibo Chen
YLYunpeng Ling
Yunpeng Ling
XWXuesheng Wang
Xuesheng Wang
JSJiajia Sun
Jiajia Sun
ZZZiyuan Zhang
Ziyuan Zhang
LGLiqiang Guo
Liqiang Guo
Acute kidney injury (AKI) is sustained by reciprocal amplification of oxidative stress, innate immune signaling, and maladaptive immune–parenchymal crosstalk. Here, we developed a lipid nanoparticle containing a ceria nanozyme and a STING‐targeting CasRx plasmid and functionalized it with D4F, an 18‐residue apolipoprotein A‐I mimetic peptide composed of D‐amino acids. The resulting D4F‐CeO 2 @LNP‐CasRx(STING) formulation retained radical‐scavenging activity, supported CasRx encapsulation, and showed enhanced cellular and renal delivery. In macrophages, the formulation reduced oxidative stress and total STING abundance together with downstream TBK1 and IRF3 phosphorylation, shifted the CD86/CD206 profile toward a less inflammatory state, and altered the secretome in a manner that protected hypoxia‐challenged tubular epithelial cells. In kidney organoids and peripheral‐blood‐mononuclear‐cell‐coupled organoid cultures, D4F functionalization improved intratissue accumulation, increased the frequency of CD4 + FOXP3 + T cells, and attenuated the hypoxia‐associated DNA damage response and tubular injury. In mice with renal ischemia–reperfusion injury, treatment reduced STING signaling in CD11b + renal macrophages, improved renal function and histology, and lowered whole‐kidney inflammatory and injury readouts. Spatial transcriptomic and proteomic analyses were consistent with contraction of inflammatory immune states and restoration of repair‐associated programs. These findings support a DNA‐delivering nanozyme strategy for renal immune‐niche modulation in AKI.